Navigation Links
Migenix to Present Celgosivir Phase II Hepatitis C Results at,Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient population at Digestive Disease Week (DDW) 2007 being held in Washington, DC May 19-24, 2007. Dr. Kelly Kaita, the Director of the Viral Hepatitis Investigative Unit (VHIU) at the Health Sciences Centre, University of Manitoba and a lead investigator in the MIGENIX Phase II study will make the presentation.

The presentation entitled: "Phase II Study of Celgosivir in Combination with Peginterferon alfa-2b and Ribavirin in Chronic Hepatitis C Genotype-1 Non-responder Patients" (Abstract # 324227) will be made on Monday, May 21, at 2:45 p.m. (EDT) in Room 206 of the Washington Convention Center. Additionally on May 20, 2007 Dr. Kaita and AnnKatrin Petersen, M.D., Vice President, Clinical Development of MIGENIX will participate in a DDW news conference highlighting progress in new and evolving areas of chronic hepatitis C therapy including celgosivir. A copy of the presentation and the related Abstract will be available at www.migenix.com following the presentation.

Research being presented at Digestive Disease Week 2007 analyzes advancements in the diagnosis of hepatitis C and therapies available to patients who suffer from the disease. DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the gastrointestinal professional. Every year DDW attracts more than 16,000 physicians, researchers and academics from around the world.

About Celgosivir (MX-3253)<
'"/>




Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), ... repair and regeneration, today announced that J.J. Finkelstein ... present a corporate overview at two upcoming investor conferences. ... SeeThruEquity 4 th Annual Microcap Conference on Thursday ... at 11:00 am EDT.  A webcast will ...
(Date:5/22/2015)... , May 22, 2015  The Mesothelioma ... diagnosed victims of mesothelioma get the best possible ... certain individuals with this rare cancer caused by ... most up-to-date information related to treatment options such ... please call the Mesothelioma Victims Center anytime at ...
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 52015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... Topsfield, MA (PRWEB) May 22, 2015 ... Keri Hart, MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President ... International, “A very important ‘language’ that impacts how ... International, the leader in long term care reimbursement, ... and education programs and talent management, launches a ...
(Date:5/22/2015)... R.I. (PRWEB) May 22, 2015 Memorial Day ... Amica Insurance is offering some tips to help ... Safety Council, there will be 383 traffic fatalities this Memorial ... from the National Highway Traffic Safety Association: , ... in the vehicle is wearing a seatbelt, whether they’re driving ...
(Date:5/22/2015)... ZH Healthcare (ZH), ... today that Bill Lane, joins ZH’s Advisory Board. ... BlueEHS,a first of its kind, Freemium SaaS, Electronic ... Health Records (EHR) with an integrated practice management ... patient portal, and more. Combined with its Revenue ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... FRIDAY, July 8 (HealthDay News) -- Young women say they flock ... their natural beauty, protects them from the sun,s rays and fills ... lasting. A deep tan may help project beauty and confidence ... give way to permanent skin damage caused by the ultraviolet rays ...
... main treatment for HER2-positive metastatic breast cancer, helps some ... Herceptin-based therapies, according to a study led by researchers ... and published in the Journal of Clinical Oncology. ... the targeted therapies, which play different roles in cancer, ...
... , FRIDAY, July 8 (HealthDay News) ... and biofeedback to help prevent chronic migraine headaches ... study suggests. Researchers compared the costs of ... drugs. After six months, minimal-contact behavioral treatment was ...
... , FRIDAY, July 8 (HealthDay News) -- Along with rising ... an open window also increases, experts say, with many children ... years and younger are treated for falls from windows, according ... 5 years, the majority of a child,s weight is concentrated ...
... For the past decade, researchers have tried to reprogram the ... one of the most sought-after cells in regenerative medicine because ... by replacing lost tissue. Now, researchers at the Perelman School ... to demonstrate the direct conversion of a non-heart cell type ...
... , FRIDAY, July 8 (HealthDay News) -- Obese people ... likely to suffer from complications than those of normal ... outcomes are often used by insurance companies, the Johns ... doctors and hospitals are reimbursed for more complex procedures ...
Cached Medicine News:Health News:A Safe Tan? No Way, Experts Say 2Health News:A Safe Tan? No Way, Experts Say 3Health News:A Safe Tan? No Way, Experts Say 4Health News:Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer 2Health News:Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer 3Health News:Windows Pose Safety Risk for Young Children, Experts Warn 2Health News:A change of heart: Penn researchers reprogram brain cells to become heart cells 2Health News:Obesity May Increase Risk of Surgical Complications 2
... its great versatility in epilation and ... the compactness and easy-transportability of the ... protocols developed for Smartepil II plus, ... indicated for hair removal of tricky ...
... Plus is a CO2 laser system ... W. Its functions in continuous and ... requiring extreme laser intervention delicacy. Excellent ... studios, it comes with a large ...
... Performance ZyDoc offers HIPAA-secure web-based access to ... days a week through the utilization of ... documents, listen to the original dictation at ... electronically sign the document, and fax to ...
Auto Refkeratomoeter...
Medicine Products: